Abstract
Deep annotation of a library of 4‐anilinoquin(az)olines led to the identification of 7‐iodo‐N‐(3,4,5‐trimethoxyphenyl)quinolin‐4‐amine 16 as a potent inhibitor (IC50=14 nM) of Protein Kinase Novel 3 (PKN3) with micromolar activity in cells. Compound 16 is a potential tool compound to study the cell biology of PKN3 and its role in pancreatic and prostate cancer and T‐cell acute lymphoblastic leukemia. These 4‐anilinoquin(az)olines may also be useful tools to uncover the therapeutic potential of PKN3 inhibition in a broad range of diseases.
Funding Information
  • Canada Foundation for Innovation (1097737)
  • Innovative Medicines Initiative (115766)
  • National Institutes of Health (1U24DK116204-01)
  • University of North Carolina at Chapel Hill (CHE-1726291)

This publication has 55 references indexed in Scilit: